APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Tyrosine Kinase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Non-Tyrosine Kinase Inhibitors Industry Growth and Trends Forecast to 2032

26 December 2025117 pages

Choose your research edition.

Industry ResearchNon-Tyrosine Kinase Inhibitors Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Tyrosine Kinase Inhibitors Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Non-Tyrosine Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Tyrosine Kinase Inhibitors Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Tyrosine Kinase Inhibitors Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Non-Tyrosine Kinase Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Non-Tyrosine Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Non-Tyrosine Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-Tyrosine Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Non-Tyrosine Kinase Inhibitors include Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GlaxoSmithKline (GSK), Onconova Therapeutics, Nerviano Medical Sciences and Jasco Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Non-Tyrosine Kinase Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Non-Tyrosine Kinase Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Non-Tyrosine Kinase Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Non-Tyrosine Kinase Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Non-Tyrosine Kinase Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Non-Tyrosine Kinase Inhibitors Market by Company

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

GlaxoSmithKline (GSK)

Onconova Therapeutics

Nerviano Medical Sciences

Jasco Pharmaceuticals

Eternity Bioscience

Daiichi Sankyo

Cyclacel Pharmaceuticals

Celgene Corporation

Carna Biosciences

AstraZeneca

Astex Pharmaceuticals

Array BioPharma

Non-Tyrosine Kinase Inhibitors Segment by Type

CDK Inhibitors

mTOR Inhibitors

RAF/MEK Inhibitors

Non-Tyrosine Kinase Inhibitors Segment by Application

Brain Cancer

Respiratory Cancer

Liver Cancer

Others

Non-Tyrosine Kinase Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Tyrosine Kinase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Tyrosine Kinase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Tyrosine Kinase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Non-Tyrosine Kinase Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Non-Tyrosine Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of CDK Inhibitors Table 2. Major Company of mTOR Inhibitors Table 3. Major Company of RAF/MEK Inhibitors Table 4. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (W Units) Table 6. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 7. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 8. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Type (2021-2026) Table 9. Global Non-Tyrosine Kinase Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 10. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2027-2032) & (W Units) Table 11. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 12. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 13. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Type (2027-2032) Table 14. Global Non-Tyrosine Kinase Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 15. North America Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (W Units) Table 16. North America Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (W Units) Table 18. Europe Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (W Units) Table 20. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (W Units) Table 22. Latin America Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (W Units) Table 24. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 25. Non-Tyrosine Kinase Inhibitors Industry Trends Table 26. Non-Tyrosine Kinase Inhibitors Industry Drivers Table 27. Non-Tyrosine Kinase Inhibitors Industry Opportunities and Challenges Table 28. Non-Tyrosine Kinase Inhibitors Industry Restraints Table 29. Global Non-Tyrosine Kinase Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Company (2021-2026) Table 31. Global Non-Tyrosine Kinase Inhibitors Sales by Company (2021-2026) & (W Units) Table 32. Global Non-Tyrosine Kinase Inhibitors Sales Share by Company (2021-2026) Table 33. Global Non-Tyrosine Kinase Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Non-Tyrosine Kinase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Non-Tyrosine Kinase Inhibitors Major Company Production Sites and Headquarters Table 36. Global Non-Tyrosine Kinase Inhibitors Company, Product Type & Application Table 37. Global Non-Tyrosine Kinase Inhibitors Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Non-Tyrosine Kinase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Non-Tyrosine Kinase Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Non-Tyrosine Kinase Inhibitors Sales by Region (2021-2026) & (W Units) Table 42. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 43. Global Non-Tyrosine Kinase Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 44. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Region (2021-2026) Table 45. Global Non-Tyrosine Kinase Inhibitors Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Non-Tyrosine Kinase Inhibitors Sales by Region (2027-2032) & (W Units) Table 47. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 48. Global Non-Tyrosine Kinase Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 49. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Region (2027-2032) Table 50. Global Non-Tyrosine Kinase Inhibitors Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (W Units) Table 53. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 54. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 55. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Application (2021-2026) Table 56. Global Non-Tyrosine Kinase Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 57. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2027-2032) & (W Units) Table 58. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 59. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 60. Global Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Application (2027-2032) Table 61. Global Non-Tyrosine Kinase Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 62. North America Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (W Units) Table 63. North America Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (W Units) Table 65. Europe Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (W Units) Table 67. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (W Units) Table 69. Latin America Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (W Units) Table 71. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Novartis Non-Tyrosine Kinase Inhibitors Product Portfolio Table 76. Novartis Recent Development Table 77. Merck KGaA Company Information Table 78. Merck KGaA Business Overview Table 79. Merck KGaA Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolio Table 81. Merck KGaA Recent Development Table 82. Roche Company Information Table 83. Roche Business Overview Table 84. Roche Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Roche Non-Tyrosine Kinase Inhibitors Product Portfolio Table 86. Roche Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolio Table 96. Pfizer Recent Development Table 97. GlaxoSmithKline (GSK) Company Information Table 98. GlaxoSmithKline (GSK) Business Overview Table 99. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolio Table 101. GlaxoSmithKline (GSK) Recent Development Table 102. Onconova Therapeutics Company Information Table 103. Onconova Therapeutics Business Overview Table 104. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolio Table 106. Onconova Therapeutics Recent Development Table 107. Nerviano Medical Sciences Company Information Table 108. Nerviano Medical Sciences Business Overview Table 109. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolio Table 111. Nerviano Medical Sciences Recent Development Table 112. Jasco Pharmaceuticals Company Information Table 113. Jasco Pharmaceuticals Business Overview Table 114. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio Table 116. Jasco Pharmaceuticals Recent Development Table 117. Eternity Bioscience Company Information Table 118. Eternity Bioscience Business Overview Table 119. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolio Table 121. Eternity Bioscience Recent Development Table 122. Daiichi Sankyo Company Information Table 123. Daiichi Sankyo Business Overview Table 124. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolio Table 126. Daiichi Sankyo Recent Development Table 127. Cyclacel Pharmaceuticals Company Information Table 128. Cyclacel Pharmaceuticals Business Overview Table 129. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio Table 131. Cyclacel Pharmaceuticals Recent Development Table 132. Celgene Corporation Company Information Table 133. Celgene Corporation Business Overview Table 134. Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolio Table 136. Celgene Corporation Recent Development Table 137. Carna Biosciences Company Information Table 138. Carna Biosciences Business Overview Table 139. Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolio Table 141. Carna Biosciences Recent Development Table 142. AstraZeneca Company Information Table 143. AstraZeneca Business Overview Table 144. AstraZeneca Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolio Table 146. AstraZeneca Recent Development Table 147. Astex Pharmaceuticals Company Information Table 148. Astex Pharmaceuticals Business Overview Table 149. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio Table 151. Astex Pharmaceuticals Recent Development Table 152. Array BioPharma Company Information Table 153. Array BioPharma Business Overview Table 154. Array BioPharma Non-Tyrosine Kinase Inhibitors Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolio Table 156. Array BioPharma Recent Development Table 157. North America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 158. North America Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 159. North America Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 160. North America Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032) & (W Units) Table 161. North America Non-Tyrosine Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 162. North America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. North America Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 164. North America Non-Tyrosine Kinase Inhibitors Market Share by Country (2021-2026) Table 165. North America Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. North America Non-Tyrosine Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 167. Europe Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 168. Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 169. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 170. Europe Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032) & (W Units) Table 171. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 172. Europe Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Europe Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 174. Europe Non-Tyrosine Kinase Inhibitors Market Share by Country (2021-2026) Table 175. Europe Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Europe Non-Tyrosine Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 177. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 178. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 179. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 180. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032) & (W Units) Table 181. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 182. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 184. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Share by Country (2021-2026) Table 185. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 187. Latin America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 188. Latin America Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 189. Latin America Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 190. Latin America Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032) & (W Units) Table 191. Latin America Non-Tyrosine Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 192. Latin America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 193. Latin America Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 194. Latin America Non-Tyrosine Kinase Inhibitors Market Share by Country (2021-2026) Table 195. Latin America Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 196. Latin America Non-Tyrosine Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 197. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 198. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 199. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2026) Table 200. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032) & (W Units) Table 201. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 202. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 203. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 204. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Share by Country (2021-2026) Table 205. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 206. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Share Forecast by Country (2027-2032) Table 207. Key Raw Materials Table 208. Raw Materials Key Suppliers Table 209. Non-Tyrosine Kinase Inhibitors Distributors List Table 210. Non-Tyrosine Kinase Inhibitors Customers List Table 211. Research Programs/Design for This Report Table 212. Authors List of This Report Table 213. Secondary Sources Table 214. Primary Sources List of Figures Figure 1. Non-Tyrosine Kinase Inhibitors Image Figure 2. Global Non-Tyrosine Kinase Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Tyrosine Kinase Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-Tyrosine Kinase Inhibitors Sales (2021-2032) & (W Units) Figure 5. CDK Inhibitors Image Figure 6. Global CDK Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 7. mTOR Inhibitors Image Figure 8. Global mTOR Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 9. RAF/MEK Inhibitors Image Figure 10. Global RAF/MEK Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 11. Global Non-Tyrosine Kinase Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Non-Tyrosine Kinase Inhibitors Market Share by Type 2025 VS 2032 Figure 13. North America Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 14. North America Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 15. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Latin America Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Non-Tyrosine Kinase Inhibitors Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Brain Cancer Image Figure 26. Global Brain Cancer Sales YoY Growth (2021-2032) & (W Units) Figure 27. Respiratory Cancer Image Figure 28. Global Respiratory Cancer Sales YoY Growth (2021-2032) & (W Units) Figure 29. Liver Cancer Image Figure 30. Global Liver Cancer Sales YoY Growth (2021-2032) & (W Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 33. Global Non-Tyrosine Kinase Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Non-Tyrosine Kinase Inhibitors Market Share by Application 2025 VS 2032 Figure 35. North America Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 36. North America Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 37. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Latin America Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Market Share in Value by Application in 2025 Figure 45. North America Non-Tyrosine Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 46. North America Non-Tyrosine Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Non-Tyrosine Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Non-Tyrosine Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Non-Tyrosine Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. Europe Non-Tyrosine Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Non-Tyrosine Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Non-Tyrosine Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Non-Tyrosine Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Latin America Non-Tyrosine Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Non-Tyrosine Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Non-Tyrosine Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Non-Tyrosine Kinase Inhibitors Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Non-Tyrosine Kinase Inhibitors Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • CDK Inhibitors
  • mTOR Inhibitors
  • RAF/MEK Inhibitors
Applications
  • Brain Cancer
  • Respiratory Cancer
  • Liver Cancer
  • Others
Companies covered
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline (GSK)
  • Onconova Therapeutics
  • Nerviano Medical Sciences
  • Jasco Pharmaceuticals
  • Eternity Bioscience
  • Daiichi Sankyo
  • Cyclacel Pharmaceuticals
  • Celgene Corporation
  • Carna Biosciences
  • AstraZeneca
  • Astex Pharmaceuticals
  • Array BioPharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Non-Tyrosine Kinase Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Non-Tyrosine Kinase Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Non-Tyrosine Kinase Inhibitors Market by Type
  6. 1.3.1 CDK Inhibitors
  7. 1.3.2 mTOR Inhibitors
  8. 1.3.3 RAF/MEK Inhibitors
  9. 1.4 Global Non-Tyrosine Kinase Inhibitors Market Size by Type
  10. 1.4.1 Global Non-Tyrosine Kinase Inhibitors Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Non-Tyrosine Kinase Inhibitors Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Non-Tyrosine Kinase Inhibitors Industry Trends
  2. 2.2 Non-Tyrosine Kinase Inhibitors Industry Drivers
  3. 2.3 Non-Tyrosine Kinase Inhibitors Industry Opportunities and Challenges
  4. 2.4 Non-Tyrosine Kinase Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Non-Tyrosine Kinase Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by Non-Tyrosine Kinase Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by Non-Tyrosine Kinase Inhibitors Price (2021-2026)
  4. 3.4 Global Non-Tyrosine Kinase Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Non-Tyrosine Kinase Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global Non-Tyrosine Kinase Inhibitors Company, Product Type & Application
  7. 3.7 Global Non-Tyrosine Kinase Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Non-Tyrosine Kinase Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Non-Tyrosine Kinase Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Non-Tyrosine Kinase Inhibitors Tier 1, Tier 2, and Tier 3
4 Non-Tyrosine Kinase Inhibitors Regional Status and Outlook
  1. 4.1 Global Non-Tyrosine Kinase Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Non-Tyrosine Kinase Inhibitors Historic Market Size by Region
  3. 4.2.1 Global Non-Tyrosine Kinase Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Non-Tyrosine Kinase Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Non-Tyrosine Kinase Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global Non-Tyrosine Kinase Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Non-Tyrosine Kinase Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Non-Tyrosine Kinase Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Non-Tyrosine Kinase Inhibitors by Application
  1. 5.1 Non-Tyrosine Kinase Inhibitors Market by Application
  2. 5.1.1 Brain Cancer
  3. 5.1.2 Respiratory Cancer
  4. 5.1.3 Liver Cancer
  5. 5.1.4 Others
  6. 5.2 Global Non-Tyrosine Kinase Inhibitors Market Size by Application
  7. 5.2.1 Global Non-Tyrosine Kinase Inhibitors Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Non-Tyrosine Kinase Inhibitors Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis Non-Tyrosine Kinase Inhibitors Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Merck KGaA
  8. 6.2.1 Merck KGaA Company Information
  9. 6.2.2 Merck KGaA Business Overview
  10. 6.2.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolio
  12. 6.2.5 Merck KGaA Recent Developments
  13. 6.3 Roche
  14. 6.3.1 Roche Company Information
  15. 6.3.2 Roche Business Overview
  16. 6.3.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Roche Non-Tyrosine Kinase Inhibitors Product Portfolio
  18. 6.3.5 Roche Recent Developments
  19. 6.4 Eli Lilly
  20. 6.4.1 Eli Lilly Company Information
  21. 6.4.2 Eli Lilly Business Overview
  22. 6.4.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolio
  24. 6.4.5 Eli Lilly Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 GlaxoSmithKline (GSK)
  32. 6.6.1 GlaxoSmithKline (GSK) Company Information
  33. 6.6.2 GlaxoSmithKline (GSK) Business Overview
  34. 6.6.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolio
  36. 6.6.5 GlaxoSmithKline (GSK) Recent Developments
  37. 6.7 Onconova Therapeutics
  38. 6.7.1 Onconova Therapeutics Company Information
  39. 6.7.2 Onconova Therapeutics Business Overview
  40. 6.7.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolio
  42. 6.7.5 Onconova Therapeutics Recent Developments
  43. 6.8 Nerviano Medical Sciences
  44. 6.8.1 Nerviano Medical Sciences Company Information
  45. 6.8.2 Nerviano Medical Sciences Business Overview
  46. 6.8.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolio
  48. 6.8.5 Nerviano Medical Sciences Recent Developments
  49. 6.9 Jasco Pharmaceuticals
  50. 6.9.1 Jasco Pharmaceuticals Company Information
  51. 6.9.2 Jasco Pharmaceuticals Business Overview
  52. 6.9.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
  54. 6.9.5 Jasco Pharmaceuticals Recent Developments
  55. 6.10 Eternity Bioscience
  56. 6.10.1 Eternity Bioscience Company Information
  57. 6.10.2 Eternity Bioscience Business Overview
  58. 6.10.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolio
  60. 6.10.5 Eternity Bioscience Recent Developments
  61. 6.11 Daiichi Sankyo
  62. 6.11.1 Daiichi Sankyo Company Information
  63. 6.11.2 Daiichi Sankyo Business Overview
  64. 6.11.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolio
  66. 6.11.5 Daiichi Sankyo Recent Developments
  67. 6.12 Cyclacel Pharmaceuticals
  68. 6.12.1 Cyclacel Pharmaceuticals Company Information
  69. 6.12.2 Cyclacel Pharmaceuticals Business Overview
  70. 6.12.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
  72. 6.12.5 Cyclacel Pharmaceuticals Recent Developments
  73. 6.13 Celgene Corporation
  74. 6.13.1 Celgene Corporation Company Information
  75. 6.13.2 Celgene Corporation Business Overview
  76. 6.13.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolio
  78. 6.13.5 Celgene Corporation Recent Developments
  79. 6.14 Carna Biosciences
  80. 6.14.1 Carna Biosciences Company Information
  81. 6.14.2 Carna Biosciences Business Overview
  82. 6.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolio
  84. 6.14.5 Carna Biosciences Recent Developments
  85. 6.15 AstraZeneca
  86. 6.15.1 AstraZeneca Company Information
  87. 6.15.2 AstraZeneca Business Overview
  88. 6.15.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolio
  90. 6.15.5 AstraZeneca Recent Developments
  91. 6.16 Astex Pharmaceuticals
  92. 6.16.1 Astex Pharmaceuticals Company Information
  93. 6.16.2 Astex Pharmaceuticals Business Overview
  94. 6.16.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
  96. 6.16.5 Astex Pharmaceuticals Recent Developments
  97. 6.17 Array BioPharma
  98. 6.17.1 Array BioPharma Company Information
  99. 6.17.2 Array BioPharma Business Overview
  100. 6.17.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolio
  102. 6.17.5 Array BioPharma Recent Developments
7 North America by Country
  1. 7.1 North America Non-Tyrosine Kinase Inhibitors Sales by Country
  2. 7.1.1 North America Non-Tyrosine Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America Non-Tyrosine Kinase Inhibitors Market Size by Country
  6. 7.2.1 North America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Non-Tyrosine Kinase Inhibitors Sales by Country
  2. 8.1.1 Europe Non-Tyrosine Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Non-Tyrosine Kinase Inhibitors Market Size by Country
  6. 8.2.1 Europe Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Non-Tyrosine Kinase Inhibitors Sales by Country
  2. 10.1.1 South America Non-Tyrosine Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America Non-Tyrosine Kinase Inhibitors Market Size by Country
  6. 10.2.1 South America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Non-Tyrosine Kinase Inhibitors Value Chain Analysis
  2. 12.1.1 Non-Tyrosine Kinase Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Non-Tyrosine Kinase Inhibitors Production Mode & Process
  7. 12.2 Non-Tyrosine Kinase Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Non-Tyrosine Kinase Inhibitors Distributors
  10. 12.2.3 Non-Tyrosine Kinase Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst